Type Ii Diabetes Mellitus clinical trials

Explore recruiting type ii diabetes mellitus clinical trials.

Recruiting type ii diabetes mellitus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Type Ii Diabetes Mellitus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A research study comparing the effect of different dosing conditions on blood levels of semaglutide in a new tablet composition in healthy participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study comparing exposure of semaglutide and dapagliflozin dosed orally as mono-components versus in a fixed-dose combination

Germany

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

Austria

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes inadequately controlled on diet and exercise.

Italy, Hungary, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of healthy Japanese participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Type Ii Diabetes Mellitus trials by city

Type Ii Diabetes Mellitus in Toronto Type Ii Diabetes Mellitus in Vancouver Type Ii Diabetes Mellitus in Montreal Type Ii Diabetes Mellitus in Calgary Type Ii Diabetes Mellitus in Edmonton Type Ii Diabetes Mellitus in Ottawa Type Ii Diabetes Mellitus in Winnipeg Type Ii Diabetes Mellitus in Quebec City Type Ii Diabetes Mellitus in Hamilton Type Ii Diabetes Mellitus in Kitchener Type Ii Diabetes Mellitus in London Type Ii Diabetes Mellitus in Halifax Type Ii Diabetes Mellitus in New York Type Ii Diabetes Mellitus in Los Angeles Type Ii Diabetes Mellitus in Chicago Type Ii Diabetes Mellitus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease